This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

PharmaSphere: Global Generics Strategy - Key Drivers, Markets And Trends In 2013

NEW YORK, April 11, 2013 /PRNewswire/ -- announces that a new market research report is available in its catalogue:

PharmaSphere: Global Generics Strategy - Key Drivers, Markets and Trends in 2013

PharmaSphere: Global Generics Strategy - Key Drivers, Markets and Trends in 2013


GlobalData's "PharmaSphere: Global Generics Strategy - Key Drivers, Markets and Trends in 2013" report, provides strategic analysis of the global generics industry. It discusses key trends, significant M&A deals in 2012, and describes the operations strategy of these companies. Furthermore, it includes a geographical segmentation of the top 30 companies into various markets, including the BRIC countries ( Brazil, Russia, India, and China), to identify the top players in each market.

Throughout the report, GlobalData's analysts provide you with expert insight, expanding on each strategy and factor discussed, with the aim of providing you with the tools needed for making informed business decisions


- The report identifies the key generic players in various markets, including a special focus on emerging markets such as India, China, Russia, and Brazil. - Furthermore, it provides detailed analysis of the various generic markets including the US, Europe, APAC, and BRIC.- The report contains expert insights on the corporate strategies of generic companies seeking competitive advantage in the highly competitive generics industry.

Reasons to buy

- Identify the key generic players in various markets, including the emerging markets such as India, China, Russia, and Brazil- Analyze and track the strategies that successful generic companies are using to gain share in the increasingly competitive market- Understand the key drivers and trends in the global generics industry- Use this information as an independent source for your due diligence and transaction strategy

Table of Contents

1 Table of Contents 51.1 List of Tables 91.2 List of Figures 92 Introduction 112.1 Report Scope 112.2 Upcoming Related Reports 122.3 Recently Published Reports 133 Generics Industry Dynamics 143.1 Generics to the Fore 143.1.1 Imminence of the Patent Cliff 143.1.2 Rising healthcare expenditures prompts many governments to resort to generics to save costs 193.1.3 Focus on emerging markets 203.1.4 Generic companies continuously drill holes in Big Pharma's deep pockets 214 Strategic Deals Trends 244.1 Big Pharma's need to plug its revenue gap 264.2 Governments cut healthcare spending as financial austerity spreads globally 264.3 Low margins in the generics business necessitate scale economies 264.4 Highlighted Deals from 2012 274.4.1 Watson Closes $5.5 billion Purchase of Actavis 284.4.2 Mylan Enters into Generics Partnership with Pfizer 314.4.3 Merck and Supera Farma Laboratórios 355 Generics in North America 375.1 Overview 375.2 United States 385.2.1 The US Pharmaceutical Industry 385.2.2 Key Players 505.2.3 Outlook 516 Generics in the Asia-Pacific (APAC) 526.1 Overview 526.2 Australia: Healthcare Policy Reform and the Generics Business 536.2.1 Prescription Drug Regulation and Pricing in Australia 536.2.2 The Australian Generics Business Environment 586.2.3 Key Players 636.2.4 Australia's Healthcare Reform and Impact on the Role of Generics 646.3 Japan 676.3.1 The Japanese Pharmaceutical Market 676.3.2 Perception of Generics in Japan 696.3.3 Impact of Pharmacies on Generics Substitution 706.3.4 Generics Approval and Market Exclusivity 716.3.5 Key Players 727 Generics in Europe and Africa 747.1 Overview 747.2 Europe 757.2.1 The Increasing Burden on Healthcare 757.2.2 Case Study: Germany 777.3 Africa 817.3.1 The Need for Local Production 817.3.2 Low regulatory compliance and infrastructure result in a weak pharmaceutical industry 827.3.3 Low standard of living makes medicines unaffordable, discouraging local players 827.3.4 Global organizations and multinationals are standardizing Africa's pharmaceutical space 837.3.5 Pharmaceutical Manufacturing Plan for Africa 847.3.6 Case Study: South Africa 848 Generics in the BRIC Countries 948.1 Overview 948.2 Brazil 958.2.1 Latin America Market Leader 958.2.2 Government industrial policies will aid further development of the pharmaceutical industry 968.2.3 Generics in Brazil 978.2.4 Key Players 998.3 Russia 1018.3.1 The New Federal Law on Health in the Russian Federation 1018.3.2 Pharma 2020 will further encourage domestic production in Russia 1038.3.3 Healthy financial situation places less pressure on the Russian government to reduce healthcare costs 1038.3.4 Key Player 1048.4 India 1058.4.1 Absence of product patents before 2005 triggered the birth of the Indian generics market 1058.4.2 Quality manufacturing facilities create an ideal environment for generics to thrive 1068.4.3 Inter-firm competition enables capabilities development 1078.4.4 Policies and initiatives encourage participation in generics manufacturing by driving demand 1078.4.5 Increased competition from larger multinationals may stymie the development of smaller domestic players 1088.4.6 Growing pressures on patent laws could challenge domestic generics manufacturers 1098.4.7 Key Market Players 1108.4.8 Outlook 1138.5 China 1158.5.1 Parallel demographics presents different scenarios on China's pharmaceutical industry 1158.5.2 A dysfunctional healthcare system provides little incentive for generics substitution 1168.5.3 Soaring healthcare expenditures pressure China's financial stability 1178.5.4 Healthcare reform will level the pharmaceutical industry playing field and foster the growth of the generics sector 1188.5.5 Key Players 1198.5.6 Market Outlook 1209 Strategic Outlook 1219.1 Patent expiries and evolution of the regulatory landscape fuel generics 1219.1.1 US patent expiry wave presents a unique opportunity for generic manufacturers 1219.1.2 Government reforms will continue to facilitate generic prescribing 1229.1.3 Consolidation sweeps through the generics sector 1229.1.4 India's generic companies are an emerging force in the global generics market 12310 Appendix 12410.1 Bibliography 12410.2 Abbreviations 13210.3 Research Methodology 13710.3.1 Coverage 13710.3.2 Secondary Research 13810.3.3 Expert Panel Validation 13810.4 About the Authors 13810.4.1 Analyst 13810.4.2 Director of Healthcare Industry Dynamics 13910.4.3 Global Head of Healthcare Research and Consulting 13910.5 About the Industry Dynamics Team 14010.6 About GlobalData 14010.7 Contact Us 14110.8 Disclosure Information 14110.9 Disclaimer 141

List of Tables

Table 1: First-Time Generic Drug Approvals, 2012 15Table 2: Health Expenditures of OECD Countries as a Percentage of GDP, 2001–2010 19Table 3: Recent and Upcoming US Patent Expirations, with FY2011 and FY2012 Sales Data 22Table 4: Overview of the Collaboration and M&A Deals in this Report, 2012 27Table 5: Watson Acquires Actavis in $5.5 Billion Deal 30Table 6: Pfizer's Collaboration with Mylan Pharmaceuticals 34Table 7: Merck's JV with Supera Farma Laboratórios 36Table 8: Generics-Focused Deals by Major Drug Companies, 2008–2012 62Table 9: Initial Phase of Price Reductions through Disclosure Agreements, 2009 66Table 10: Top 10 Pharmaceutical Companies in Brazil, 1998 and 2007 96Table 11: China: Urban and Rural Pharmaceutical Market Size, 2012 115

List of Figures

Figure 1: NME Approvals by the FDA, 1996–2012 14Figure 2: Trend in Deals in the Generics Industry, 2008–2012 25Figure 3: Pfizer: Emerging Markets Revenues as a Percentage of Annual Revenues, 2006–2012 32Figure 4: Merck: Market focus1, 2007–2011 35Figure 5: North American Generics Market Landscape – FY2012 Corporate Revenue Growth vs. North American Revenue Growth 37Figure 6: Domestic Exports of Pharmaceutical Products from the US, 2000–2011 39Figure 7: R&D Spending by PhRMA Members, 2004-2011 40Figure 8: US Healthcare Expenditures and GDP, 2002–2011 43Figure 9: US per Capita Healthcare Expenditures and GDP, 2001–2010 44Figure 10: FDA Generic Drug Review Process 46Figure 11: Generic Drug Approvals in the US, 2008–2012 47Figure 12: APAC Generics Market Landscape – FY2012 Corporate Revenue Growth vs. APAC Revenue Growth 52Figure 13: Australia: Trends in Prescription Volume and Government Costs, 2000–2011 59Figure 14: Australian Government's and Patients' Contributions to PBS Costs, 2005–2011 60Figure 15: Average Birth Life Expectancies1 in the APAC Region, 2012 68Figure 16: EMEA Generics Market Landscape – FY2012 Corporate Revenue Growth vs. EMEA Revenue Growth 74Figure 17: Birth Life Expectancies in Europe, 2010 vs. 2003 75Figure 18: Public-Debt and Budget-Deficit-to-GDP Ratios in the Eurozone, 2012 76Figure 19: Generics vs. Branded Products Split in South Africa, 2002–2006 87Figure 20: Generics vs. Branded Products Split in South Africa, 2008–2012 88Figure 21: Generics Utilization in South Africa, 2012–2020 92Figure 22: BRIC Generics Market Landscape – FY2012 Corporate Revenue Growth vs. BRIC Revenue Growth 94Figure 23: Russia, Percentage of Total Healthcare Expenditures by Revenue Source, 2009 102Figure 24: Value of Pharmaceutical Exports from India, 2002–2011 106Figure 25: Indian Generics Market Landscape – FY2012 Corporate Revenue Growth vs. India Revenue Growth 110Figure 26: Total and Government Healthcare Expenditures* in China, 2001–2011 117

To order this report: Generic_Drug Industry: PharmaSphere: Global Generics Strategy - Key Drivers, Markets and Trends in 2013

__________________________Contact Clare: US:(339) 368 6001 Intl:+1 339 368 6001

SOURCE Reportlinker

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,798.49 -14.90 -0.08%
S&P 500 2,090.11 +1.24 0.06%
NASDAQ 5,127.5250 +11.3820 0.22%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs